menu
    • menu

    Company profile for AiCuris

    NEW Drugs in Dev: 3
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech compan...
    AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AiCurisGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Friedrich-Ebert-Str. 475 Building 302 D-42117 Wuppertal
    Telephone
    Telephone
    +49 (0)202 317 63 - 0
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aicuris.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Asahi Kasei to buy Germany's Aicuris for $920M
    Asahi Kasei to buy Germany's Aicuris for $920M

    27 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/asahi-kasei-accrue-german-aicuris-920-million-rd-portfolio-boost

    FIERCE BIOTECH
    27 Feb 2026
    Share Share
    Pritelivir Shows Superior Ph 3 Efficacy in HIV Patients with HSV
    Pritelivir Shows Superior Ph 3 Efficacy in HIV Patients with HSV

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244926/0/en/Pritelivir-Demonstrates-Superior-Efficacy-in-People-Living-with-HIV-with-Refractory-HSV-in-Phase-3-PRIOH-1.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    1. Aicuris Shows Positive Ph 3 Data for Pritelivir at TANDEM
    1. Aicuris Shows Positive Ph 3 Data for Pritelivir at TANDEM

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232727/0/en/Aicuris-Presents-Positive-Phase-3-Data-for-Pritelivir-in-Immunocompromised-Patients-with-Refractory-Herpes-Simplex-Virus-at-TANDEM.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Aicuris To Present Pritelivir Phase 3 HSV Data At Tandem
    Aicuris To Present Pritelivir Phase 3 HSV Data At Tandem

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228292/0/en/Aicuris-Announces-Pritelivir-Phase-3-HSV-Data-to-Be-Presented-as-Late-Breaking-Oral-Presentation-at-Tandem.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Smartbax Acquires Aicuris' Antibacterial Compound
    Smartbax Acquires Aicuris' Antibacterial Compound

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221336/0/en/smartbax-in-licenses-lead-antibacterial-compound-targeting-Gram-negative-infections-from-Aicuris.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Aicuris Reveals Pritelivir Phase 2 Success And AIC468 Safety Data
    Aicuris Reveals Pritelivir Phase 2 Success And AIC468 Safety Data

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169156/0/en/Aicuris-Presents-Positive-Phase-2-Results-for-Pritelivir-and-Favorable-Phase-1-Safety-Data-for-AIC468-at-ID-Week-2025.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search